Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

PwC's midyear assessment validates what we have tracked since January: 2026 is a historic dealmaking year. The firm counted $65B in Q1 alone, nearly double Q1 2025, with 16 deals exceeding $1B. PwC said the activity was "focused on differentiated science, GLP-1 expansion and next-generation modalities including RNA medicines, antibody-drug conjugates and gene editing." BioSpace added that PwC declared the biopharma ecosystem "back to full health." The firm also noted the IPO window is open and that biotechs should be prepared with a dual-track process (IPO and M&A) to maximize optionality. Lilly's 13th deal of the year, acquiring 4E Therapeutics for oral non-opioid pain, adds yet another therapeutic area to a portfolio that already spans obesity, oncology, cell therapy, narcolepsy, gene editing, vaccines, myelofibrosis, kidney disease, and now chronic pain. The pain space is strategically interesting: the opioid crisis created enormous unmet need for effective non-addictive pain medications, and MNK inhibitors represent a novel mechanism that avoids the CNS effects of both opioids and gabapentinoids. Meanwhile, the UniQure story is a rare good-news FDA regulatory reversal: the agency changed its mind and will now accept an accelerated approval filing for Huntington's gene therapy, a condition with no disease-modifying treatments. 👉 Read Full Analysis

🔮 What To Watch

📊 M&A & Capital Markets

PwC: Biopharma Ecosystem 'Back to Full Health'

PwC's Pharmaceutical and Life Sciences US Deals 2026 midyear outlook reported that biopharma dealmaking strengthened sharply at the start of the year, with deal value surpassing $65B in Q1, nearly double the level seen a year earlier and one of the strongest quarterly performances in recent years. Key findings:

BioSpace noted that "precision science is ruling the M&A scene as pharmas prepare for loss of exclusivity on key products." The PwC data aligns with CNBC's $106B figure (through early June, broader methodology), Reuters' $84B Q1 (Dealogic), and BioWorld's $93B through April.

Lilly Acquires 4E Therapeutics for Non-Opioid Pain Pipeline LLY

Lilly acquired 4E Therapeutics, adding a pipeline of oral MNK (MAP kinase-interacting kinase) inhibitors for chronic pain without the CNS side effects linked to opioids and many existing therapies, according to The Pharma Letter. Financial terms were not disclosed. This is Lilly's 13th announced deal of 2026, expanding the company's therapeutic footprint into pain for the first time this year.

🔬 Gene Therapy & Regulatory

UniQure Plans Q3 Huntington's Gene Therapy Filing After FDA Reversal QURE

UniQure announced plans for a Q3 2026 submission of its Huntington's disease gene therapy after the FDA reversed its previous position and agreed to accept an accelerated approval filing, according to BioSpace. Fierce Biotech reported the FDA "gave the biotech the OK to file for accelerated approval after previously demanding data from another trial." Huntington's disease is a fatal neurodegenerative disorder with no approved disease-modifying treatments. If accepted and approved, this would be one of the most significant gene therapy approvals in history, addressing a condition that has resisted every prior therapeutic approach.

🏢 Oncology

Jazz Signs TCE Discovery Deal with AbCellera JAZZ

Jazz Pharmaceuticals signed a preclinical research collaboration with AbCellera for the discovery and development of next-generation T-cell engagers (TCEs), according to BioSpace and Fierce Biotech. Jazz is paying $56M upfront and is eligible to pay up to $792M in milestones for each of three initial programs, plus tiered royalties. The deal diversifies Jazz's oncology strategy beyond its established hematology portfolio and adds bispecific antibody capabilities through AbCellera's high-throughput antibody discovery platform.

💊 Anti-Infective / AMR

FDA Approves First Oral Carbapenem for Complicated UTIs

The FDA approved GSK and Spero Therapeutics' Utebzi (tebipenem pivoxil) as the first oral carbapenem antibiotic for complicated urinary tract infections, according to The Pharma Letter. Carbapenems are powerful last-resort antibiotics typically administered intravenously. An oral formulation allows outpatient treatment, reducing hospital stays and healthcare costs. The approval addresses a critical gap in AMR treatment at a time when LimmaTech (acquired by Lilly for $780M in May) and other companies are building anti-infective pipelines to combat growing resistance.

📅 The Week Ahead

Multiple data sources now confirm 2026 as a historic M&A year, but the numbers differ based on methodology:

The differences reflect scope (U.S. vs. global), definition (M&A only vs. M&A + licensing), and size thresholds. But the directional signal is the same across every dataset: 2026 is running at approximately 2x the pace of 2025, driven by patent cliff urgency, abundant cash, and a productive pipeline of de-risked acquisition targets.

💊 Lilly's 13 Deals: The Therapeutic Map

Nine therapeutic areas. Eight modalities. Thirteen deals. Total disclosed value: $30B+. No other pharma company has executed this breadth in this timeframe.

📊 The Non-Opioid Pain Opportunity

The U.S. chronic pain market exceeds $10B annually but has been dominated by opioids, NSAIDs, and gabapentinoids, all of which carry significant side effect or addiction risk. The opioid crisis created both political will and commercial opportunity for non-addictive alternatives. MNK inhibitors represent a novel mechanism: MAP kinase-interacting kinases are involved in pain signaling pathways but not in the reward pathways that drive opioid addiction.

Lilly's 4E acquisition positions the company to develop oral pain treatments that address a massive unmet need without the regulatory and political baggage of opioid-adjacent mechanisms. The pain space has attracted increased pharma attention: AbbVie/Haisco signed a Nav1.8 deal in April, and multiple companies are pursuing non-opioid mechanisms in late-stage development.

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →